Trial description:
a randomised phase II feasibility study of INTERmittent versus continuous dosing of oral targeted combination therapy In patients with BRAFV600 mutant stage 3 unresectable or metastatic Melanoma
Contact name:
Dr Pippa Corrie
Trial start date:
Friday, November 3, 2017
Trial end date:
Friday, April 17, 2020
Trial tumour type:
Skin & melanoma
Show on Radiotherapy:
No